09/30/2021 at 12:01 am CEST
Diabetes is estimated to affect 9.3% of the world’s population. In this scenario, promoting research into this chronic pathology is one of the goals of Danish pharmaceutical company Novo Nordisk, whose pharmacological innovation improves the health of many people around the world.
It was in 1921 that a team of Canadian researchers discovered the insulin molecule, ushering in a period of novelty in the management of this pathology.
Two years later, in 1923, Nordisk Insulin Laboratorium began producing insulin in Europe, after August and Marie Krogh imported the technique for extracting and purifying this hormone to Denmark from Canada.
From that moment, people diagnosed with this pathology were able to significantly improve their life expectancy.
THE BEST NEWS
The laboratory continued its research in this area and, recently, succeeded in synthesizing a protein for the treatment of type 2 diabetes, consisting in the development of an oral alternative to injectable GLP-1.
A discovery that represents a technological step when it is possible to synthesize a protein in oral form, which offers an alternative for patients who have difficulty injecting.
In this sense, today we have better medicines than ever before, although the number of people with diabetes continues to grow at an alarming rate.
New treatment options take type 2 diabetes beyond glycemic control with the introduction of GLP-1 agonists and later SGLT-2 inhibitors.
The GLP-1 therapeutic class reduces sugar levels by improving the natural secretion of insulin. According to sources from the laboratory, these advances respond to continuous research to improve treatments, and are in line with the objective of:
“Eradicate diabetes, help improve individual and public health, prevent the rise of type 2 diabetes and obesity, and provide access to accessible treatments for vulnerable patients”
–
